Thanks to JAMA Internal Medicine for publishing my story about two patient encounters as an ICU resident with Cleveland Clinic IM which served as important lessons in communication that I will never forget. Grateful to their families for letting me tell these stories jamanetwork.com/journals/jamai…

What are the latest research advances in #coloncancer screening and detection? Suneel Kamath MD from @clevelandclinic shares the latest cutting-edge advances. ow.ly/cLRr50SFgo8 #colorectalcancer

Why are #coloncancer cancer cases in young people on the rise? Suneel Kamath MD from @clevelandclinic discusses potential risk factors. ow.ly/iwGy50SHcXo #colorectalcancer

🧪 Suneel Kamath MD discusses exciting data from the CodeBreaK 300 trial along with Arvind Dasari, MD, MS and Sakti Chakrabarti, MD. 📺 The panel also discusses the use of ctDNA in adjuvant settings and sequencing challenges in #colorectal cancer: buff.ly/46bFuDi

Family history and #coloncancer: Suneel Kamath MD from @clevelandclinic explains how genetic testing helps. ow.ly/2RIh50SJ7H0 #colorectalcancer

Thank you for your unwavering support throughout this journey MinhTri Nguyen, MD (he/him)

Important #pallonc #supponc study published in JAMA Network Open Adding Olanzapine💊 (Zyprexa) high dose 10mg qhs Day 1⃣-3⃣to #MEC regimens ⬆️ complete 🤢 resolution rates from 82% to 91% ‼️Impacts many #GIonc regimen (ox/iri)‼️ OncoAlert🚨 jamanetwork.com/journals/jaman…

💉FOLFOX/Xelox + beva vs. 5FU/cape +beva in first line treatment of metastatic CRC in older patients Journal of Clinical Oncology ➡️Median age 80 and 79 ❌No difference in PFS, 10 vs 9.4 mo. ❌No difference in OS, 19.7 vs 21.3 mo. ❌grade ≥3 AEs 69% vs. 52% ❗️~65% left sided and ~36% RAS WT

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma | Nature Communications. Interesting article on Lenvatinib nature.com/articles/s4146…

Proud to be an Associate Editor alongside Yanin Chávarri A. Dimitrios Colevas MD Maryam Lustberg MD, MPH, FASCO Cathy Handy Marshall, MD MPH Mark Lewis, MD, FASCO Jordi Remon Fidel Rubagumya , MD, MMed, MPH with Pamela Kunz, MD, FASCO at the helm

Looking Back, Facing Forward (LBFF) is coming up September 14th (virtually) For individuals in the BRCA1/2 and PALB2 community and their families to learn about updates. Registration below: lp.constantcontactpages.com/ev/reg/ktev6es… Dana-Farber’s Breast Oncology Center Dana-Farber Division of Population Sciences BIDMC Mass General Cancer Center

My Top 10 Gastrointestinal Cancer Abstracts #ESMO24 ESMO - Eur. Oncology

#Juniorfaculty 👋. As a Section Editor, PLS help us review manuscripts. There ARE benefits: 🔷Understanding the landscape of #Cancer 🔷 Path to serve on the Editorial Board 🔷 Provide insight 🔷 Be an "expert" in your field 🔷 Promotion to Assoc Prof/Prof Vanderbilt-Ingram Cancer Center

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies & for steering drug development Annals of Oncology doi.org/10.1016/j.anno… 👏Excellent concept ESMO - Eur. Oncology

The outstanding work with our internal medicine resident Dr Ferrel and Dr Guven is out ‼️ ✳️We investigated common molecular pathway alterations along patients with young onset CRC ‼️ ✳️Similar rates of WNT pathway alterations but lower incidence of TGF-beta alterations ‼️

This new paper finds that the microbes in our food remain in our body: 3% of the adult gut microbiome are food microbes. But it doesn’t say which microbes/foods are best to eat & why. Do we know this? Do we have validation of good food => good microbe? cell.com/cell/fulltext/…

Alternating gemcitabine/nab-paclitaxel and gemcitabine vs continuous gemcitabine/nab-paclitaxel after induction Tx of #PDAC The Lancet Oncology doi.org/10.1016/S2468-… 🔎 ALPACA phs 2, 325 pts 👉Similar OS, but improved tolerability 🧐Alternating schedule may be considered ESMO - Eur. Oncology

📢Colorectal cancer abstracts in #ESMO24 ESMO - Eur. Oncology ✅515MO - Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) ✅516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line

It was my honor to be at AKMG meeting to deliver the keynote on “Role of doctor in the Age of Fourth Industrial Revolution! “

Looking forward to it!